Verbascoside represses malignant phenotypes of esophageal squamous cell carcinoma cells by inhibiting CDC42 via the HMGB1/RAGE axis

Hum Exp Toxicol. 2022 Jan-Dec:41:9603271221127429. doi: 10.1177/09603271221127429.

Abstract

Background: As an aggressive human malignancy, esophageal squamous cell carcinoma (ESCC) is prevalent globally, especially in China. Verbascoside (VE) exerts anti-cancer effects in several human cancers. This work was to investigate the effects of VE on ESCC cells.

Methods: Esophageal squamous cell carcinoma cell proliferation, apoptosis, migration, and invasion were assessed by CCK-8, TUNEL, and Transwell assays. Gene and protein levels were detected by RT-qPCR and western blotting. CDC42 activity was evaluated by G-lisa assay.

Results: Verbascoside significantly inhibited cell proliferation, migration, and invasion and induced cell apoptosis in ESCC cells. Furthermore, it was found that VE markedly inhibited HMGB1 and RAGE expression in a dose-dependent manner. Besides, HMGB1/RAGE upregulation partially reversed the anti-cancer effects of VE on ESCC cells. VE repressed HMGB1/RAGE-induced CDC42 activation in ESCC cells. In addition, ML141-mediated CDC42 inactivation further enhanced the effect of VE on ESCC cell proliferation, apoptosis, migration, and invasion.

Conclusions: Our findings indicated that VE has significant anti-tumor potential in ESCC by suppressing HMGB1/RAGE-dependent CDC42 activation.

Keywords: CDC42; HMGB1; RAGE; Verbascoside; esophageal squamous cell carcinoma.

MeSH terms

  • Cell Line, Tumor
  • Cell Movement
  • Esophageal Neoplasms* / drug therapy
  • Esophageal Neoplasms* / metabolism
  • Esophageal Squamous Cell Carcinoma* / drug therapy
  • Esophageal Squamous Cell Carcinoma* / genetics
  • Esophageal Squamous Cell Carcinoma* / metabolism
  • Glucosides* / pharmacology
  • Glucosides* / therapeutic use
  • HMGB1 Protein / drug effects
  • HMGB1 Protein / metabolism
  • Humans
  • Neoplasm Invasiveness
  • Phenotype
  • Polyphenols* / pharmacology
  • Polyphenols* / therapeutic use
  • Receptor for Advanced Glycation End Products / drug effects
  • Receptor for Advanced Glycation End Products / metabolism
  • Sincalide / chemistry
  • cdc42 GTP-Binding Protein* / drug effects
  • cdc42 GTP-Binding Protein* / metabolism

Substances

  • Glucosides
  • HMGB1 Protein
  • Polyphenols
  • Receptor for Advanced Glycation End Products
  • acteoside
  • cdc42 GTP-Binding Protein
  • Sincalide